SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.

Saved in:
Bibliographic Details
Published inArchives of neurology (Chicago) Vol. 78; no. 7; p. 880
Main Authors van Kempen, Zoé L E, Strijbis, Eva M M, Al, Marissa M C T, Steenhuis, Maurice, Uitdehaag, Bernard M J, Rispens, Theo, Killestein, Joep
Format Journal Article
LanguageEnglish
Published United States American Medical Association 01.07.2021
Subjects
Adult
Aged
Antibodies
Antibodies, Viral - analysis
Cohort Studies
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 - immunology
Female
Humans
Immune response
Immunology
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - complications
Multiple Sclerosis - epidemiology
Netherlands - epidemiology
Prospective Studies
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Netherlands
Online AccessGet full text

Cover

More Information
Summary:This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.
ISSN:2168-6149
2168-6157
DOI:10.1001/jamaneurol.2021.1364